Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 6/2007

01-04-2007 | Leading Article

Therapeutic Potential of Vasopressin Receptor Antagonists

Authors: Farhan Ali, Maya Guglin, Peter Vaitkevicius, Dr Jalal K. Ghali

Published in: Drugs | Issue 6/2007

Login to get access

Abstract

Arginine vasopressin (AVP) is a neuropeptide hormone that plays an important role in circulatory and sodium homeostasis, and regulating serum osmolality. Several clinical conditions have been associated with inappropriately elevated levels of AVP including heart failure, cirrhosis of the liver and the syndrome of inappropriate secretion of antidiuretic hormone. Three receptor subtypes that mediate the actions of AVP have been identified (V1A, V2 and V1b).
Activation of V1A receptors located in vascular smooth muscle cells and the myocardium results in vasoconstriction and increased afterload and hypertrophy. The V2 receptors located primarily in the collecting tubules mediate free water absorption. The V1B receptors are located in the anterior pituitary and mediate adrenocorticotropin hormone release.
The cardiovascular and renal effects of AVP are mediated primarily by V1A and V2 receptors. Antagonism of V1A receptors results in vasodilatation and antagonism of V2 receptors resulting in aquaresis, an electrolyte-sparing water excretion. Several non-peptide AVP antagonists (vasopressin receptor antagonists [VRAs]) also termed ‘vaptans’ have been developed and are vigorously being studied primarily for treating conditions characterised by hyponatraemia and fluid overload.
Conivaptan is a combined V1A/V2-receptor antagonist that induces diuresis as well as haemodynamic improvement. It has been shown in clinical trials to correct euvolaemic and hypervolaemic hyponatraemia, and has been approved by the US FDA for the treatment of euvolaemic hyponatraemia as an intravenous infusion. Tolvaptan, a selective V2-receptor antagonist, has undergone extensive clinical studies in the treatment of hyponatraemia and heart failure. It has been shown to effectively decrease fluid in volume overloaded patients with heart failure and to correct hyponatraemia. A large outcome study (n = 4133 patients) will define its role in the management of heart failure. Lixivaptan and satavaptan (SR-121463) are other selective V2-receptor antagonists being evaluated for the treatment of hyponatraemia.
In addition, a potential role for the vaptans in attenuating polyuria in nephrogenic diabetes insipidus and cyst development in polycystic kidney disease is being explored.
Ongoing clinical trials should further define the scope of the potential therapeutic role of VRAs.
Literature
1.
Guyton AC. The body fluids and kidneys. In: Guyton AC, Hall JE, editors. Textbook of medical physiology. Philadelphia (PA): WB Saunders Company, 2006: 291–414
2.
Burrell LM, Risvanis J, Johnston CI, et al. Vasopressin receptor antagonism: a therapeutic option in heart failure and hypertension. Exp Physiol 2000; 85: 259S–65SPubMedCrossRef
3.
Hupf H, Grimm D, Riegger GAJ, et al. Evidence for a vasopressin system in the rat heart. Circ Res 1999; 84: 365–70PubMedCrossRef
4.
Brooks VL, Keil LC, Reid IA. Role of the renin-angiotensin system in the control of vasopressin secretion in conscious dogs. Circ Res 1986; 58: 829–38PubMedCrossRef
5.
6.
Tahara A, Tomura Y, Wada K, et al. Effects of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res 1998; 38: 198–205PubMedCrossRef
7.
Fukuzawa J, Haneda T, Kikuchi K. Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol Cell Biochem 1999; 195: 93–8PubMedCrossRef
8.
Nakamura Y, Haneda T, Osakie J, et al. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V, a receptor. Eur J Pharmacol 2000; 39: 39–48CrossRef
9.
Nielsen S, Kwon TH, Christensen BM, et al. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999; 10: 647–63PubMed
10.
Sonnenburg WK, Smith WL. Regulation of cyclic AMP metabolism in rabbit cortical collecting tubule cells by prostaglandins. J Biol Chem 1988; 263: 6155–60PubMed
11.
Bernat A, Hoffmann P, Dumas A, et al. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs. J Pharmacol Exp Ther 1997; 282: 597–602PubMed
12.
Lolait SJ, O’Carroll AM, Mahan LC, et al. Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci USA 1995; 92: 6783–7PubMedCrossRef
13.
Rouleau J-L, Packer M, Moye L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994; 24: 583–91PubMedCrossRef
14.
Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724–9PubMedCrossRef
15.
Goldsmih SR, Francis GS, Cowley AW, et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983; 1: 1385–90CrossRef
16.
17.
Palmer BF, Gates JR, Lader M. Causes and management of hyponatremia. Ann Pharmacother 2003; 37: 1694–702PubMedCrossRef
18.
Upadhyay A, Jaber B, Madias N. Incidence and prevalence of hyponatremia. Am J Med 2006; 119: S30–5PubMedCrossRef
19.
Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003; 40: 1801–7
20.
Barter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 1967; 42: 790–806CrossRef
21.
Bichet D, Szatalowicz V, Chaimovitz C, et al. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 1982; 96: 413–7PubMed
22.
Schrier RW, Ecder T. Unifying hypothesis of body fluid volume regulation: implications for cardiac failure and cirrhosis. Mt Sinai J Med 2001; 68: 350–61PubMed
23.
Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341: 577–85PubMedCrossRef
24.
Domanski M, Tian X, Haigney M, et al. Diuretic use, progressive heart failure, and death in patients in the DIG study. J Cardiac Failure 2006; 12 (5): 327–32CrossRef
25.
Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003; 42: 705–8PubMedCrossRef
26.
Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999; 100: 1311–5PubMedCrossRef
27.
28.
Zerbe R, Stropes L, Robertson G. Vasopressin function in the syndrome of inappropriate antidiuresis. Ann Rev Med 1980; 31: 315–27PubMedCrossRef
29.
Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes insipisus. J Am Soc Nephrol 2005; 16: 2836–46PubMedCrossRef
30.
Bernier V, Morello JP, Zarruk A, et al. Pharmacologic chaperones as a potential treatment for x-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 2006; 17: 232–43PubMedCrossRef
31.
Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system,part 1: receptor physiology. Crit Care 2003; 7 (6): 427–34PubMedCrossRef
32.
Dunser MW, Mayr AL, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003; 107 (18): 2313–9PubMedCrossRef
33.
Lindner KH, Dirks B, Strohmenger HU, et al. Randomized comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet 1997 Feb 22; 349 (9051): 535–7PubMedCrossRef
34.
Gavras I, Gavras H. Role of vasopressin in hypertensive disorders. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press Ltd, 1995
35.
Ribiero A, Mulinasi R, Gavras I, et al. Sequential elmination of pressor mechanisms in severe hypertention in humans. Hypertension 1986; Suppl. I: 1169-73
36.
Burrell LM, Phillips PA, Stephenson JM, et al. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension 1994; 23 (Pt 1): 737–43PubMedCrossRef
37.
Bursztyn M, Breshnahan M, Gavras I, et al. Pressor hormones in elderly hypertensive persons. Racial Differ Hypertens 1990; 15: 188–92
38.
Bakris G, Bursztyn M, Gavras I, et al. Role of vasopressin in essential hypertension: racial differences. J Hypertens 1997; 15: 545–50PubMedCrossRef
39.
40.
Gattone VH, Wang X, Harris PC, et al. Inhibition of renal cystic disease development and progression by vasopressin V2 receptor antagonist. Nat Med 2003; 9: 1323–6PubMedCrossRef
41.
Yamamura Y, Ogawa H, Yamashita H, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992; 105: 787–91PubMedCrossRef
42.
Lee CR, Watkins ML, Patterson JH, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J2003; 146: 9–181PubMedCrossRef
43.
Clair MJ, King MK, Goldberg A, et al. Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure. J Pharmacol Exp Ther 2000; 293: 852–60PubMed
44.
Share L. Interrelations between vasopressin and the rennin-angiotensin system. Fed Proc 1979; 38: 2267–71PubMed
45.
Cowley AW Jr, Lieard JF. Vasopressin and arterial pressure regulation. Hypertension 1988; 11: 125–32
46.
Tabrizchi R, King K, Pang C. Vascular role of vasopressin in the presence and absence of influence from angiotensin II or alpha adrenergic system. Can J Physiol Pharmacol 1986; 64: 1143–8PubMedCrossRef
47.
Gavras H, Ribeiro AB, Kohlmann O, et al. Effects of a specific inhibitor of the vascular action of vasopressin in humans. Hypertension 1984; 6 Suppl. II: 56–60
48.
Burrell LM, Phillips PA, Rolls KA, et al. Vascular responses to vasopressin antagonists in man and rat. Clin Sci 1994; 87: 389–95PubMed
49.
Hirano T, Yamamura Y, Nakamura S, et al. Effects of the V2-receptor and antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 2000; 292: 288–94PubMed
50.
Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107: 2690–6PubMedCrossRef
51.
Gheorghiade M, Gattis WA, O’Connor CM, et al., on behalf of the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive HF (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening HF: a randomized controlled trial. JAMA 2004; 291 (16): 1963–71PubMedCrossRef
52.
Udelson JE, Orlandi C, O’Brien T, et al. Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo-controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination [abstract]. J Am Coll Cardiol 2002; 39: 156ACrossRef
53.
Udelson JE, the METEOR Trial Investigators. Multicenter, randomized double-blind, placebo-controlled, efficacy study on the effects of oral tolvaptan on LV dilatation and function in patients with HF and LV systolic dysfunction. The 9th Annual Scientific Meeting of Heart Failure Society of America; 2005 Sep 18–21; Boca Raton (FL)
54.
Gheorghiade M, Orlanid C, Burnett J, et al., on behalf of the EVERST Study Investigators. Rationale and design of the multicenter, randomized double-blind, placebo-controlled study to evaluate the efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail 2005; 11: 260–9PubMedCrossRef
55.
Thibonnier M. Vasopressin receptor antagonists in heart failure. Curr Opin Pharmacol 2003; 3: 683–7PubMedCrossRef
56.
Abraham WT, Shamshiraz AA, McFann K, et al. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antaonist, in New York Heart Association Functional Class II and III chronic heart failure patients. J Am Coll Cardiol 2006; 47: 1615–21PubMedCrossRef
57.
Wong F, Blei AT, Blendis LM, et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, plavebo-controlled trial. Hepatology 2003; 37: 182–91PubMedCrossRef
58.
Gerbes AL, Gulberg V, Gines P, et al., on behalf of the VPA Study Group. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003; 124: 933–9PubMedCrossRef
59.
Soupart A, Gross P, Legros JJ, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with SR 121 463 B, an orally active, nonpeptide, vasopressin V-2 receptor antagonist [abstract no. SU-PO140]. J Am Soc Nephrol 2004; 15: 563A
60.
Yatsu T, Tomura Y, Tahara A, et al. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1a and V2 receptor antagonist, in dogs. Eur J Pharmacol 1997; 321: 225–30PubMedCrossRef
61.
Tahara A, Tomura Y, Wada K, et al. Pharmacological profile of YM087, a novel potent vasopressin V1a and V2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 1997; 282: 301–8PubMed
62.
Yatsu T, Tomura Y, Tahara A, et al. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1a and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol 1999; 376: 239–46PubMedCrossRef
63.
Verbalis JG, Bisaha JG, Smith N. Novel vasopressin V-1A and V2 antagonist (conivaptan) increases serum sodium concentration and effective water clearance in patients with hyponatremia. Circulation 2004; 110 (17I): 723
64.
Ghali J, Koren MJ, Taylor JR, et al., on behalf of the Conivaptan Study Group. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic of hypervolemic hyponatremia. J Clin Endocrinol Metab 2006; 91: 2145–52PubMedCrossRef
65.
Russell S, Selaru P, Pyne DA, et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin Antagonist in CHF patients undergoing Exercise) trial. Am Heart J 2003; 145: 179–86PubMedCrossRef
66.
Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104: 2417–23PubMedCrossRef
67.
Ghali JK, Verbalis JG, Gross P, et al. Conivaptan, a novel arginine vasopressin antagonist, increased serum sodium concentration in patients with heart failure and euvolemic or hypervolemic hyponatremia [abstract]. J Am Coll Cardiol 2006; 47: 62A
Metadata
Title
Therapeutic Potential of Vasopressin Receptor Antagonists
Authors
Farhan Ali
Maya Guglin
Peter Vaitkevicius
Dr Jalal K. Ghali
Publication date
01-04-2007
Publisher
Springer International Publishing
Published in
Drugs / Issue 6/2007
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200767060-00002

Other articles of this Issue 6/2007

Drugs 6/2007 Go to the issue

Current Opinion

Cyclo-Oxygenase-2 and its Inhibition in Cancer

Therapy In Practice

Management of Hepatitis C Infection after Liver Transplantation

Review Article

Pharmacological Treatments for Basal Cell Carcinoma

Leading Article

Satraplatin in Hormone-Refractory Prostate Cancer and Other Tumour Types

Review Article

Aerosolised Antibacterials for the Prevention and Treatment of Hospital-Acquired Pneumonia

Adis Drug Evaluation

Exenatide